NCT01964534 - Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

December 12, 2013

Primary Completion Date

February 28, 2017

Study Completion Date

July 31, 2017

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

ABI-007

ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)

DRUG

Gemcitabine

1000 mg/m² IV /30min (day 1, day 8, day 15)

DRUG

simplified LV5FU2

Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)

Trial Locations (15)

Institut de Cancérologie de l'Ouest - Réné Gauducheau, Saint-Herblain

Institut de cancérologie de l'Ouest - Paul Papin, Angers

Institut Sainte Catherine, Avignon

Hôpital Avicenne, Bobigny

Hôpital Beaujon, Clichy

Hôpital Henri Mondor, Créteil

Hôpital Privé Jean Mermoz, Lyon

CHU la Timone, Marseille

Centre Hospitalier Layné, Mont-de-Marsan

Hôpital Européen Georges Pompidou, Paris

Hôpital Pitié-Salpêtrière, Paris

Hôpital Saint Antoine, Paris

Institut Mutualiste Montsouris, Paris

CHU de Reims Hôpital Robert Debré, Reims

Hôpital Trousseau - CHRU Tours, Tours